> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Senate Judiciary Committee Clears 5 Drug Bills
- URL: https://www.fdaweb.com/senate-judiciary-committee-clears-5-drug-bills/
- Published: 2023-02-09T12:00:00.000Z
- Updated: 2026-09-14T18:15:16.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153749

The Senate Judiciary [Committee 2/9](https://www.judiciary.senate.gov/download/executive-business-meeting-results-2023-02-09?ref=fdaweb.com) cleared five drug-related bills and they now head to the Senate floor for consideration. The bipartisan bills were voted out of committee the previous Congress.

In opening remarks, Sen. **Chris Coons** (D-DE) said more has to be done to ensure Americans have access to affordable pharmaceuticals. “And we are showing today, a history of this committee from the last Congress moving forward to this, that we can work together to issue legislation that deals with drug pricing and availability,” he said. “And I congratulate my colleagues… for their work on addressing the role played by pharmacy benefit managers, the companies that administer and manage prescription drug plans and the drug distribution process, and the role that the USPTO and FDA can play in addressing anti-competitive business practices.”

The bills voted out of committee are:

- [S.142](https://www.congress.gov/bill/118th-congress/senate-bill/142?ref=fdaweb.com) \- A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
- [S.79](https://www.congress.gov/bill/118th-congress/senate-bill/79/committees?ref=fdaweb.com), A bill to establish an interagency task force between the United States Patent and Trademark Office and FDA for purposes of sharing information and providing technical assistance with respect to patents,
- [S.148](https://www.congress.gov/bill/118th-congress/senate-bill/148?ref=fdaweb.com) \- A bill to enable to Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
- [S.113](https://www.congress.gov/bill/118th-congress/senate-bill/113?s=1&r=10&ref=fdaweb.com) – A bill to require the Federal Trade Commission to study the role of intermediaries (pharmacy benefit managers) in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations.
- [S.150](https://www.congress.gov/bill/118th-congress/senate-bill/150?ref=fdaweb.com) \- A bill to amend the Federal Trade Commission Act to prohibit product hopping and anticompetitive practices related to patents being filed by brand manufacturers to block generic and biosimilar competition.